- Home
- WRBY vs CNTA Comparison
WRBY vs CNTA Comparison
Compare WRBY & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | CNTA |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WRBY | CNTA |
|---|---|---|
| Price | $23.79 | $29.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $26.67 | ★ $40.89 |
| AVG Volume (30 Days) | ★ 3.1M | 1.0M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.88 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $871,905,000.00 | N/A |
| Revenue This Year | $14.81 | N/A |
| Revenue Next Year | $15.98 | N/A |
| P/E Ratio | $2,363.00 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $13.63 | $9.60 |
| 52 Week High | $31.00 | $30.58 |
Technical Indicators
Market Signals| Indicator | WRBY | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 65.96 |
| Support Level | $21.47 | $24.62 |
| Resistance Level | $28.86 | $30.29 |
| Average True Range (ATR) | 1.55 | 1.23 |
| MACD | -0.19 | 0.20 |
| Stochastic Oscillator | 15.14 | 97.45 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.